Detection of prostate cancer: comparison of cancer detection rates of sextant and extended ten-core biopsy protocols.
OBJECTIVE
To compare the cancer detection rates of sextant and ten- core biopsy protocol amongst patients being evaluated for prostate cancer.


METHODS
This is a prospective study involving 125 men with suspicion of prostate cancer. They all had an extended 10-core transrectal digitally-guided prostatic biopsy using Tru-Cut needle. Indications for biopsy were presence of one or more of the following: elevated Prostate Specific Antigen (PSA), abnormal Digital Rectal Examination (DRE) findings and abnormal prostate scan. Sextant biopsies were collected first, followed by four lateral biopsies in all patients. Both groups of specimen were kept and analyzsed separately by the same pathologist. The cancer detection rates of sextant and extended (combination of sextant and lateral) 10-core biopsy protocols were determined and compared. Pearson's Chi square and McNemar tests at two degrees of freedom with level of significance set at 0.05 ( P <0.005) were used to determine the statistical significance.


RESULTS
The overall cancer detection rate of 10-core prostate biopsy was 48.8%. Of all positive biopsies, the sextant biopsy protocol detected 52 cancers (85.2%) while the lateral biopsy protocol detected 58 cases (95.1%). Three (3) cancers were detected by the sextant protocol only while the lateral protocol detected nine (9) cancers where sextant technique was negative for malignancy. Ten-core extended protocol showed a statistically significant increase of 14.8% over the traditional sextant. (P=0.046). The overall complication rate of ten-core biopsy was 26.4% and the procedure was well tolerated in most patients.


CONCLUSIONS
We conclude that a ten-core prostate biopsy protocol significantly improves cancer detection and should be considered as the optimum biopsy protocol.
Department of Surgery, Lagos University Teaching Hospital, Lagos Nigeria. rwaleojewola@yahoo.com
R W
RW
Ojewola
K H
KH
Tijani
E A
EA
Jeje
C C
CC
Anunobi
M A
MA
Ogunjimi
E V
EV
Ezenwa
O S
OS
Ogundiniyi
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000473:pathology; D000368:Aged; D001707:Biopsy, Needle / Q000009:adverse effects / Q000379:methods; D002985:Clinical Protocols / Q000592:standards*; D057186:Comparative Effectiveness Research / Q000379:methods; D051517:Digital Rectal Examination / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading / Q000379:methods; D009549:Nigeria; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000473:pathology; D058996:Quality Improvement
D017430:Prostate-Specific Antigen